2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
3
Fallopian Tube Neoplasms
3
Carcinoma, Ovarian Epithelial
3
Unspecified Adult Solid Tumor, Protocol Specific
1
Prostatic Neoplasms
1
Peritoneal Neoplasms
1
Neoplasms
1
Metastatic Castrate- Resistant Prostate Cancer
1
Interventions
Hyperthermic Intraperitoneal Chemotherapy
28
Paclitaxel
24
Cisplatin
23
Oxaliplatin
18
Cytoreduction Surgical Procedures
17
Carboplatin
17
Fluorouracil
14
Bevacizumab
10
Mitomycin
9
Leucovorin
9
Doxorubicin
9
Docetaxel
6
Gemcitabine
5
130-nm albumin-bound paclitaxel
5
Surgical Procedures, Operative
4
Neoadjuvant Therapy
4
Blood Specimen Collection
4
Albumin-Bound Paclitaxel
4
sodium thiosulfate
3
liposomal doxorubicin
3
catumaxomab
3
Taxes
3
Laparoscopy
3
Drug Therapy
3
Chemotherapy, Adjuvant
3
tremelimumab
2
relacorilant
2
pembrolizumab
2
olaparib
2
nintedanib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Peritoneal Neoplasms
×
phenoxodiol
×
Clear all
NCT00382811
2016-07-18
OVATURE
MEI Pharma, Inc.
Phase 3
Completed
142 enrolled